{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:15:19Z","timestamp":1789661719365,"version":"4.0.1"},"reference-count":14,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"unspecified","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,7,7]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Phase 3 trials of the anti-amyloid monoclonal antibodies lecanemab and donanemab in Alzheimer\u2019s disease demonstrated modest slowing of cognitive decline over 18 months. Subsequent open-label extensions (OLE) suggested greater long-term benefit based on comparisons with historical untreated cohorts, which are vulnerable to selection and attrition bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We simulated longitudinal Clinical Dementia Rating\u2013Sum of Boxes trajectories using mixed-effects models calibrated to reproduce published means, variances and attrition patterns from the Clarity-AD and TRAILBLAZER-ALZ 2 trials, separately for early- and delayed-start cohorts and in combined analyses. Observed annualised slopes were also directly compared between double-blind (DB) and OLE phases. Placebo effects were estimated by comparing DB placebo arms with matched untreated historical cohorts derived from published natural history data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Simulations closely reproduced reported trajectories. In both trials, the early-start cohorts showed significantly faster annualised decline during OLE than during DB treatment (lecanemab \u2206=0.53; 95%\u2009CI 0.40 to 0.66; donanemab \u2206=0.66; 95%\u2009CI 0.41 to 0.91), whereas delayed-start cohorts showed no meaningful phase-related differences. OLE decline rates approximated those observed in DB placebo groups. In the lecanemab trial, DB placebo participants declined more slowly than matched untreated controls; decline in the donanemab trial varied by baseline severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite selective retention favouring slower progressors, both lecanemab and donanemab accelerated cognitive decline during OLE phases and paralleled placebo-level declines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001649","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:25:11Z","timestamp":1786361111000},"page":"e001649","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer\u2019s disease"],"prefix":"10.1136","volume":"8","author":[{"given":"Alok K","family":"Dwivedi","sequence":"first","affiliation":[{"name":"Center for Integrated Biostatistics and Epidemiology, Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri School of Medicine, Columbia, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno P","family":"Imbimbo","sequence":"additional","affiliation":[{"name":"Research & Development Department, Chiesi Farmaceutici SpA, Parma, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Abanto","sequence":"additional","affiliation":[{"name":"James J. and Joan A. Gardner Family Center for Parkinson\u2019s disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-136X","authenticated-orcid":false,"given":"Alberto J","family":"Espay","sequence":"additional","affiliation":[{"name":"James J. and Joan A. Gardner Family Center for Parkinson\u2019s disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026081300400664000_8.2.e001649.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2026081300400664000_8.2.e001649.2","unstructured":"Sims JR , Zimmer JA , Evans CD , et al . Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA: The Journal of the American Medical Association 2023."},{"key":"2026081300400664000_8.2.e001649.3","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70905","article-title":"Long\u2010term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: Results from the clarity AD open\u2010label extension study","volume":"21","author":"van Dyck","year":"2025","journal-title":"Alzheimer's & Dementia"},{"key":"2026081300400664000_8.2.e001649.4","doi-asserted-by":"crossref","first-page":"100446","DOI":"10.1016\/j.tjpad.2025.100446","article-title":"Donanemab in early symptomatic Alzheimer\u2019s disease: results from the TRAILBLAZER-ALZ 2 long-term extension","volume":"13","author":"Zimmer","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"key":"2026081300400664000_8.2.e001649.5","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000409"},{"key":"2026081300400664000_8.2.e001649.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2007.00821.x"},{"key":"2026081300400664000_8.2.e001649.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.01.010"},{"key":"2026081300400664000_8.2.e001649.8","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jalz.2012.01.005","article-title":"Progression of Alzheimer\u2019s disease as measured by Clinical Dementia Rating Sum of Boxes scores","volume":"9","author":"Williams","year":"2013","journal-title":"Alzheimer's & Dementia"},{"key":"2026081300400664000_8.2.e001649.9","unstructured":"Eisai News Release . New clinical data demonstrates three years of continuous treatment with dual-acting LEQEMBI\u00ae (lecanemab-irmb) continues to significantly benefit early Alzheimer's disease patients presented at AAIC 2024. 2024."},{"key":"2026081300400664000_8.2.e001649.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2026.100511","article-title":"Long-term extension data do not robustly support clinical disease course modification with donanemab","volume":"13","author":"Hazan","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"key":"2026081300400664000_8.2.e001649.11","doi-asserted-by":"crossref","unstructured":"Flanders MD , Caunca M , La Joie R , et al . Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials. JAMA Neurol 2026.:e261240. doi:10.1001\/jamaneurol.2026.1240","DOI":"10.1001\/jamaneurol.2026.1240"},{"key":"2026081300400664000_8.2.e001649.12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaneurol.2025.3869","article-title":"Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"82","author":"Lu","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026081300400664000_8.2.e001649.13","unstructured":"Bowman Rogers M . Plaque Removal as Surrogate? Statisticians Say Not So Fast. [online]. Available: https:\/\/www.alzforum.org\/news\/research-news\/plaque-removal-surrogate-statisticians-say-not-so-fast [Accessed 18 May 2026]."},{"key":"2026081300400664000_8.2.e001649.14","unstructured":"Bowman Rogers M . Signs of lasting benefit from amyloid immunotherapy? alzheimer research forum. 2025. Available: https:\/\/www.alzforum.org\/news\/conference-coverage\/signs-lasting-benefit-amyloid-immunotherapy [Accessed 2 Mar 2026]."}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:40:21Z","timestamp":1786606821000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjno-2026-001649"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001649","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}